ACIS · AI BIOTECH WEEKLY · ISSUE 001 · 2026.08.12
From platform narratives to commercial and clinical proof
AI Biotech Weekly | Issue 001
Recursion, Schrödinger and Insilico continue to advance partnerships with major pharma. Commercial validation is strengthening, but clinical success remains the ultimate determinant of long-term value.
01 · EXECUTIVE SUMMARY
Executive Summary
但 AI 可以压缩药物发现时间，并不能消除毒性、疗效失败、人体复杂性和监管风险。
AI can compress discovery timelines, but it cannot eliminate toxicity, efficacy failures, human complexity or regulatory risk.
02 · PLATFORM WATCH
Three Platforms to Watch
研究优先级不是简单比较谁的模型更强，而是比较现金储备、合作质量、里程碑兑现、临床阶段和融资生存能力。
The priority is not simply model quality, but cash runway, partnership quality, milestone delivery, clinical stage and financing resilience.
03 · BIG PHARMA SIGNAL
Big Pharma Is Paying
下一道门槛是 Phase II / Phase III：只有人体疗效和安全性数据，才能把平台估值真正转化为药物价值。
The next gate is Phase II and Phase III. Human efficacy and safety data are required to convert platform valuations into drug value.
04 · INVESTMENT VIEW
Investment View
最大风险仍是生物学本身，其次是持续烧钱、融资稀释、合作终止和临床进度延迟。
Biology remains the primary risk, followed by cash burn, financing dilution, partnership termination and clinical delays.
WEEKLY SCORECARD
Weekly Score
Pharma partnerships and licensing payments delivered clearer commercial proof.
Platform value is now tested by both commercial payments and clinical milestones.
Prefer diversified exposure and require milestone proof for individual names.